Seer, Inc. (SEER)
| Market Cap | 94.02M -16.4% |
| Revenue (ttm) | 15.17M -0.9% |
| Net Income | -70.49M |
| EPS | -1.25 |
| Shares Out | 54.98M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 106,695 |
| Open | 1.750 |
| Previous Close | 1.720 |
| Day's Range | 1.710 - 1.770 |
| 52-Week Range | 1.650 - 2.410 |
| Beta | 1.59 |
| Analysts | Strong Buy |
| Price Target | 4.00 (+133.92%) |
| Earnings Date | Aug 5, 2026 |
About SEER
Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome to improve human health in the United States, China, Australia, Europe, Israel, Japan, and South Africa. The company offers Proteograph Product Suite, an integrated solution, which includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company also offers ... [Read more]
Financial Performance
In 2025, Seer, Inc.'s revenue was $16.58 million, an increase of 16.99% compared to the previous year's $14.17 million. Losses were -$73.60 million, -15.01% less than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for SEER stock is "Strong Buy." The 12-month stock price target is $4.0, which is an increase of 133.92% from the latest price.
News
Radoff-JEC issue statement on CEO Farokhzad’s history of ‘value destruction’
Bradley L. Radoff and Michael Torok, together with certain of their affiliates, the “Radoff-JEC Group,” who collectively own approximately 7.7% of the outstanding shares of Seer (SEER), issued the fol...
The Radoff-JEC Group Highlights Seer Inc.'s and Chairman and CEO Omid Farokhzad, M.D.'s History of Value Destruction
HOUSTON--(BUSINESS WIRE)--Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group” or “we”), who collectively own approximately 7.7% of the outstanding sh...
Seer, Inc. Proxy statement: Proxy filing
Seer, Inc. filed a proxy statement on June 15, 2026, providing details for shareholder voting and corporate governance matters.
Seer, Inc. Proxy statement: Proxy filing
Seer, Inc. filed a proxy statement on June 15, 2026, providing details for shareholder voting and corporate governance matters.
Seer Board of Directors Issues Letter to Shareholders Highlighting the Company's Significant Scientific Progress and Addressing Radoff and Torok's Short-Sighted Campaign
Urges Stockholders to Vote “FOR” ONLY Seer's Director Nominees on the BLUE Proxy Card Urges Stockholders to Vote “FOR” ONLY Seer's Director Nominees on the BLUE Proxy Card
Seer, Inc. Proxy statement: Proxy filing
Seer, Inc. filed a proxy statement on June 11, 2026, providing details for shareholder voting and corporate governance matters.
Seer Files Definitive Proxy Materials and Mails Letter to Stockholders
Reinforces Seer's Clear Strategy, Strong Governance and Significant Long-Term Value Creation Opportunity Illustrates Why Radoff and Torok's Short-Term Campaign Risks Disrupting Seer's Momentum and Und...
Seer, Inc. Proxy statement: Proxy filing
Seer, Inc. filed a proxy statement on June 3, 2026, providing details for shareholder voting and corporate governance matters.
Seer, Inc. Proxy statement: Proxy filing
Seer, Inc. filed a proxy statement on June 3, 2026, providing details for shareholder voting and corporate governance matters.
Seer, Inc. Proxy statement: Proxy filing
Seer, Inc. filed a proxy statement on June 3, 2026, providing details for shareholder voting and corporate governance matters.
Seer, Inc. Proxy statement: Proxy filing
Seer, Inc. filed a proxy statement on June 1, 2026, providing details for shareholder voting and corporate governance matters.
Seer files ITC complaint against Nanomics Biotechnology
Seer (SEER) announced that it has filed a complaint at the United States International Trade Commission, or ITC, against Nanomics Biotechnology. The Brigham and Women’s Hospital has joined the ITC…
Seer Files ITC Complaint Against Nanomics
Seeks Exclusion Order Barring Importation of Infringing Proteonano Kits and Workstations Seeks Exclusion Order Barring Importation of Infringing Proteonano Kits and Workstations
The Radoff-JEC Group Calls on Seer Inc. and Its Advisors to Reevaluate Its Premium Acquisition Proposal in the Best Interests of All Stockholders
HOUSTON--(BUSINESS WIRE)--Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group” or “we”), who collectively own approximately 7.8% of the outstanding sh...
Seer to Showcase AI-Driven Multi-Cancer Screening Approach and Next-Generation Proteomics Capabilities at ASMS 2026
REDWOOD CITY, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced its participation at the 2026 A...
Seer, Inc. Proxy statement: Proxy filing
Seer, Inc. filed a proxy statement on May 22, 2026, providing details for shareholder voting and corporate governance matters.
Seer, Inc. Proxy statement: Proxy filing
Seer, Inc. filed a proxy statement on May 22, 2026, providing details for shareholder voting and corporate governance matters.
Seer’s Board unanimously rejects unsolicited proposal from Radoff-JEC Group
Seer’s (SEER) Board of Directors has thoroughly reviewed and unanimously rejected the further revised unsolicited non-binding proposal received on May 14 from Bradley L. Radoff and Michael Torok, or R...
Seer Board of Directors Unanimously Rejects Further Revised Unsolicited Proposal from Radoff-JEC Group
REDWOOD CITY, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that its Board of Directors (th...
Seer, Inc. Proxy statement: Proxy filing
Seer, Inc. filed a proxy statement on May 21, 2026, providing details for shareholder voting and corporate governance matters.
Seer, Inc. Proxy statement: Proxy filing
Seer, Inc. filed a proxy statement on May 18, 2026, providing details for shareholder voting and corporate governance matters.
Radoff, Torok submit proposal to acquire Seer for $2.40 per share in cash
Bradley Radoff and Michael Torok, who collectively own approximately 7.8% of the outstanding shares of Seer (SEER), submitted the following improved non-binding proposal to acquire the Company – their...
The Radoff-JEC Group Submits its Third Non-Binding Proposal to Acquire Seer, Inc.
HOUSTON--(BUSINESS WIRE)--Bradley L. Radoff and Michael Torok, who collectively own approximately 7.8% of the outstanding shares of Seer, Inc. (NASDAQ: SEER) (the “Company”), today submitted the follo...
Seer, Inc. Earnings Call Transcript: Q1 2026
Q1 2026 revenue declined year-over-year due to funding headwinds and competition, but operating expenses fell and net loss improved. Full-year guidance of $16–$18 million was reaffirmed, with growth expected in the second half, supported by new leadership, biobank collaborations, and continued innovation.
Seer, Inc. Earnings release: Q1 2026
Seer, Inc. released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.